NCT05018299已完成2 期
A Randomized, Placebo Controlled, Double Blind Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Multiple Intravenous Doses of FB704A in Adults With Severe Asthma
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 10
- 主要终点
- Proportion of the number of Adverse Event reported during the treatment period
研究概览
简要总结
This is a randomized, placebo controlled and double blind study to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FB704A in adult patients with severe asthma. The study comprised a 4-week screening period, a 8-week treatment period and a 12-week follow-up period.
详细描述
Approximately 20 subjects who meet the criteria for study entry are planned to be enrolled to the study. Eligible subjects will be randomized to receive placebo or FB704A in a 1:1 ratio, with an estimated 10 subjects per treatment arm.
Eligibility will be checked in patients with severe asthma during the 4-week screening period. Potential candidates should provide signed informed consent forms before starting the screening activities. The subjects will receive four dose of 4 mg/kg FB704A or placebo. The study drug will be administered as a 1-hour IV infusion.
Patients may administer Short-acting beta agonists (SABAs), such as albuterol as rescue medications as needed throughout the study.
Subjects will have site visits after receiving study drug for efficacy, safety, PK, and biomarker evaluation (see Study Flow Chart). Subjects who prematurely withdraw from the study will have an end of study (EOS) visit within 7 days.
Relative change in pre-bronchodilator FEV 1 , post-bronchodilator FEV 1, exhaled NO and asthma symptom s will be evaluated during the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.18 to ≦75 years of age, either sex, any race.
- •2.Diagnosed as severe asthma based on 2020 GINA guideline.
- •3.An ACT score is <
- •4.Induced sputum neutrophil count ≧50% of total sputum cells during Screening.
- •5.Documented diagnosis of severe asthma within past 5 years. Additionally, subjects must have at least one of the following: a) ≧12% and/or 200 mL improvement in Forced Expiratory Volume in 1 second (FEV1) post-bronchodilator, OR b) airway hyperresponsiveness (e.g., positive methacholine challenge <8 mg/mL), OR c) within the past 24 months, airway variability with a ≧12% and 200 mL change in FEV1 between clinic visits outside of respiratory infections, documented prior to Visit 1, OR d) within the past 24 months, average daily PEF variability > 10% over a 2-week period, documented prior to Visit
- •6.Nonsmoker or previous smoker with cumulative smoking history less than 10 pack-years (pack-year = 20 cigarettes smoked daily for 1 year). Previous smokers may not have smoked within 1 year prior to Screening. A smoker is defined as a subject who has taken inhaled nicotine containing products (e.g. cigarette, cigar, pipe), including e-cigarettes prior to screening.
- •7.Must not have had a severe asthma exacerbation of asthma for 4 weeks prior to Screening and must be on a stable medication regimen for asthma at least 4 weeks prior to Screening.
- •A Severe asthma exacerbation is defined as a deterioration of asthma leading to treatment for 3 days or more with systemic glucocorticoids or hospitalization or an emergency department visit leading to treatment with systemic glucocorticoids.
- •8.Must be willing to give written informed consent to participate in the study.
- •9.Must be capable of complying with the dosing regimen, adhere to the visit schedule, and participate in all treatment procedures, including sputum induction.
- •10.Female subject of childbearing potential must have a negative serum pregnancy test at Screening and must be using a medically acceptable, highly effective, adequate form of birth control (ie, failure rate <1% per year when used consistently and correctly) prior to Screening and agree to continue using it while in the study (Screening and Treatment Periods). Medically acceptable, highly effective forms of birth control are hormonal implants, oral contraceptives, medically acceptable prescribed intrauterine devices (IUDs), and monogamous relationship with a male partner who has had a vasectomy. Female subject who is not of childbearing potential must have a medical record of being surgically sterile (eg, hysterectomy, tubal ligation), or be at least 1 year postmenopausal. Absence of menses for at least 1 year will indicate that a female is postmenopausal. A female subject should be encouraged to continue using a highly effective method of birth control for 30 days following the end of treatment.
- •Male subject must agree to use an adequate form of contraception for the duration of the study and agree to have sexual relations only with women who use a highly effective birth control method.
排除标准
- •1.Chronic Obstructive Pulmonary Disease (COPD)/other relevant lung disease (other than asthma)
- •2.4 weeks prior to/or Screening: upper/lower respiratory tract infection
- •3.Screening: Inadequate amount or difficulty producing sputum
- •4.Screening: Sputum neutrophil count over 10 million/mL
- •5.Screening: peripheral blood neutrophil (PBN) count <2000/µL
- •6.Clinically significant chronic infectious disease(s) (eg, Human Immunodeficiency Virus [HIV], hepatitis B or C)
- •7.Allergy/sensitivity to study drug/excipients
- •8.Breast-feeding, pregnant/intends to become pregnant during study
- •9.Requiring mechanical ventilation for respiratory event within 6 months of Screening
- •10.Medical condition(s) (eg, hematologic, cardiovascular, renal, hepatic, neurologic, or metabolic) or medication that may interfere with effect of study medication
- •11.Within 30 days of Screening: any other investigational drug
- •12.Known history of active tuberculosis (TB) or evidence of tuberculosis infection as defined by a positive purified protein derivative (PPD) skin test and/or interferon-gamma release assay. The interferon-gamma release assay should be repeated in case of an indeterminate result
- •13.Active infection, including opportunistic infections, requiring systemic therapy within the past 2 weeks
- •14.A deep space infection within the past 2 years (including, but not limited to meningitis, epiglottitis, endocarditis, septic arthritis, fasciitis, abdominal or pleural abscess, or osteomyelitis)
- •15.History of diverticulitis, diverticulosis requiring antibiotic treatment, or other symptomatic lower gastrointestinal (GI) conditions that might predispose to perforations
- •16.Immunization with a live/attenuated vaccine within 4 weeks prior to treatment
- •17.Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured)
- •18.Liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 3x upper limit of normal
- •19.Serum bilirubin > 2x upper limit of normal
- •20.Low platelet count (<100,000/mm3)
- •21.Dyslipidemia.
- •22.Participation in any other clinical study.
- •23.Part of the staff personnel involved with the study.
- •24.Family member of investigational study staff.
研究组 & 干预措施
FB704A placebo
Placebo Comparator
placebo
干预措施: FB704A placebo (Biological)
FB704A
Experimental
Anti-IL6 antibody
干预措施: FB704A (Biological)
结局指标
主要结局
Proportion of the number of Adverse Event reported during the treatment period
时间窗: Day 57
AE
次要结局
- ACT score(Day 36, 57, 85, and 141)
- Change from baseline in Asthma control test (ACT)(Day 36, 57, 85, and 141)
- Change from baseline in sputum neutrophil counts(Day 57)
- Change from baseline in AQLQ(Day 36, 57, 85, and 141)
- Proportion of the number of AE reporting (incidence of adverse event)(12 weeks follow up)
- Change from baseline in blood neutrophil counts(Day 36, 57, 85, 113, and 141)
- Percentage of patients achieving decrease in score by greater than or equal to 0.5 points on the ACQ 5 (with a minimal importance difference improvement)(week 4, 8, 12, and 20)
- Change from baseline in ACQ-5(Day 36, 57, 85, and 141)
- Change from baseline in pre-bronchodilator FEV1 , post-bronchodilator FEV1, exhaled NO and asthma symptoms(Day 57 and 141)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusDiabetesType 1 Diabetes MellitusNCT02715193REMD Biotherapeutics, Inc.21
已完成
2 期
A Dose-Response Safety Study of ENX-102 in Patients With GADNCT06653296Engrail Therapeutics INC38
Unknown
不适用
Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With HemophiliaHIV InfectionHemophilia ANCT00797381Shanghai Public Health Clinical Center100
进行中（未招募）
1 期
A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy AdultsSafety IssuesNCT06494527Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.30
进行中（未招募）
2 期
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)Primary Immune ThrombocytopeniaNCT06594146Keymed Biosciences Co.Ltd62